Tier 2 — strong

Acute, quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower plasma angiotensin-converting enzyme activity or endothelin-1: nitric oxide

Abigail Larson, Melissa A H Witman, Yi Guo, Stephen Ives, Russell S Richardson, Richard S Bruno, Thunder Jalili, J David Symons
Nutrition research (New York, N.Y.) 2012 32(8):557

Bibliography

PubMed
PMID 22935338
DOI
10.1016/j.nutres.2012.06.018
Funding
Indexed grant support: R15 HL091493 — NHLBI NIH HHS — United States; R15 HL 091493 — NHLBI NIH HHS — United States; P01 HL 1091830 — NHLBI NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignDouble-blind placebo-controlled crossover acute blood-pressure study
ModelHuman intervention research
Sample12 men with stage 1 hypertension; 5 normotensive men in a pharmacokinetic comparison
InterventionQuercetin aglycone 1,095 mg
DurationSingle dose; assessment at 10 hours
EndpointsBlood pressure

What the study showed, in plain terms

Published in 2012, this source examined cardiovascular and metabolic health. Design: Double-blind placebo-controlled crossover acute blood-pressure study. Sample/model: 12 men with stage 1 hypertension; 5 normotensive men in a pharmacokinetic comparison. The exposure or intervention was Quercetin aglycone 1,095 mg. Follow-up or treatment period: Single dose; assessment at 10 hours.

Blood pressure decreased in the hypertensive group but not the normotensive comparison; ACE activity, endothelin/nitric oxide measures, and flow-mediated dilation did not explain the effect.

Small male-only acute experiment; durability, treatment equivalence, and cardiovascular outcomes were not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Blood pressure decreased in the hypertensive group but not the normotensive comparison; ACE activity, endothelin/nitric oxide measures, and flow-mediated dilation did not explain the effect.
  • The recorded outcome domains were Blood pressure.
  • The result applies to the tested exposure: Quercetin aglycone 1,095 mg; Single dose; assessment at 10 hours.

What this study can and cannot tell us

  • Small male-only acute experiment; durability, treatment equivalence, and cardiovascular outcomes were not established.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology